Sign In
Buy ONCT
$0.527
+0 (+0%)
At Close: Feb 28, 2025
Oncternal Therapeutics Announces the Sale of Select Development Programs and the Wind-Down of its Operations
08:00am, Tuesday, 01'st Jul 2025
SAN DIEGO, July 01, 2025 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. today announced the sale of its zilovertamab and ONCT-808 programs to Ho'ola Therapeutics, Inc. Zilovertamab is an investigati
Oncternal Therapeutics Announces Intent to Voluntarily Delist from Nasdaq and Deregister with the SEC
04:05pm, Friday, 07'th Mar 2025
SAN DIEGO, March 07, 2025 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT) (the “Company”) today announced its intention to file a Form 25 Notification of Delisting with the Securit
Oncternal Therapeutics, Inc. (ONCT) Q2 2024 Earnings Call Transcript
01:46am, Saturday, 10'th Aug 2024
Oncternal Therapeutics, Inc. (NASDAQ:ONCT ) Q2 2024 Earnings Call August 8, 2024 5:00 PM ET Company Participants Richard Vincent - Chief Financial Officer Jim Breitmeyer - President and Chief Executiv
Oncternal Therapeutics (ONCT) Reports Q2 Loss, Tops Revenue Estimates
06:31pm, Thursday, 08'th Aug 2024
Oncternal Therapeutics (ONCT) came out with a quarterly loss of $2.89 per share versus the Zacks Consensus Estimate of a loss of $3.03. This compares to loss of $3 per share a year ago.
Oncternal Therapeutics Provides Business Update and Announces Second Quarter 2024 Financial Results
04:01pm, Thursday, 08'th Aug 2024
SAN DIEGO, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today provi
Oncternal Therapeutics to Provide Business Update and Report Second Quarter 2024 Financial Results
04:05pm, Thursday, 01'st Aug 2024
SAN DIEGO, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today annou
Oncternal Therapeutics to Present in JonesTrading Healthcare Summit
04:05pm, Thursday, 11'th Jul 2024
SAN DIEGO, July 11, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today annou
SAN DIEGO, May 30, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announ
Oncternal Therapeutics, Inc. (ONCT) Q1 2024 Earnings Call Transcript
06:34pm, Thursday, 09'th May 2024
Oncternal Therapeutics, Inc. (NASDAQ:ONCT ) Q1 2024 Earnings Call Transcript May 9, 2024 5:00 PM ET Company Participants Richard Vincent - CFO Dr. James Breitmeyer - President and CEO Dr. Salim Yazji
Oncternal Therapeutics (ONCT) Reports Q1 Loss, Tops Revenue Estimates
06:20pm, Thursday, 09'th May 2024
Oncternal Therapeutics (ONCT) came out with a quarterly loss of $2.83 per share versus the Zacks Consensus Estimate of a loss of $2.88. This compares to loss of $4 per share a year ago.
Oncternal Therapeutics Provides Business Update and Announces First Quarter 2024 Financial Results
04:01pm, Thursday, 09'th May 2024
SAN DIEGO, May 09, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today provid
All You Need to Know About Oncternal Therapeutics (ONCT) Rating Upgrade to Buy
01:01pm, Wednesday, 08'th May 2024
Oncternal Therapeutics (ONCT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Oncternal Therapeutics to Provide Business Update and Report First Quarter 2024 Financial Results
04:05pm, Thursday, 02'nd May 2024
SAN DIEGO, May 02, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announ
Oncternal Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
09:00am, Wednesday, 01'st May 2024
SAN DIEGO, May 01, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announ
SAN DIEGO, April 18, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today anno
